| 0.408 0.008 (2%) | 03-12 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.62 | 1-year : | 0.73 |
| Resists | First : | 0.53 | Second : | 0.62 |
| Pivot price | 0.48  |
|||
| Supports | First : | 0.37 | Second : | 0.31 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.5 |
| MA(100) : | 0.98 |
MA(250) : | 1.08 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 14.1 |
| RSI | RSI(14): 30.4 |
|||
| 52-week | High : | 3.32 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ JUNS ] has closed above bottom band by 24.4%. Bollinger Bands are 2.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.42 - 0.42 | 0.42 - 0.43 |
| Low: | 0.39 - 0.39 | 0.39 - 0.39 |
| Close: | 0.4 - 0.4 | 0.4 - 0.4 |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Mon, 02 Mar 2026
Parkinson’s trial and Nugevia revenue put Jupiter Neurosciences on BIO stage - Stock Titan
Mon, 02 Mar 2026
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 - GlobeNewswire
Fri, 27 Feb 2026
Jupiter Neurosciences Receives Nasdaq Deficiency Notices, Faces Delisting - TipRanks
Fri, 27 Feb 2026
Jupiter Neurosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Wed, 25 Feb 2026
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago - Sahm
Fri, 20 Feb 2026
Jupiter Neurosciences Amends Yorkville Financing Agreement Terms - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 54 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 238 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -355 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.78 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|